Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 16,943.39% | 98.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 16,943.39% | 98.68% | |||
| Cost of Revenue | -17.70% | -13.36% | |||
| Gross Profit | 4,524.93% | 24.65% | |||
| SG&A Expenses | 59.64% | 21.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.11% | -1.44% | |||
| Operating Income | 2,312.41% | 7.83% | |||
| Income Before Tax | 4,617.97% | 51.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4,617.97% | 51.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4,617.97% | 51.49% | |||
| EBIT | 2,312.41% | 7.83% | |||
| EBITDA | 2,315.75% | 7.84% | |||
| EPS Basic | 4,591.28% | 51.73% | |||
| Normalized Basic EPS | 2,590.91% | 8.33% | |||
| EPS Diluted | 4,561.54% | 51.73% | |||
| Normalized Diluted EPS | 2,572.73% | 8.33% | |||
| Average Basic Shares Outstanding | 0.74% | 0.30% | |||
| Average Diluted Shares Outstanding | 1.49% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||